The Lupus Foundation of America (LFA) proudly presented eight abstracts and sessions during the 2025 American College of Rheumatology (ACR) Convergence with the goal of advancing science, improving ...

The Lupus Foundation of America (LFA) celebrated exceptional lupus researchers at the 20th Anniversary Evelyn V. Hess ...

Supporting lupus patients and advocates in Arizona.

The U.S. Food and Drug Administration (FDA) has approved Gazyva® (obinutuzumab), developed by Genentech, as a treatment for ...

The Lupus Foundation of America (LFA) and its funded researchers will unveil the latest advances in patient-centered research ...

The Lupus Foundation of America is dedicated to improving the quality of life for all people affected by lupus through programs of research, education, and advocacy.

Medicare Part D provides prescription drug coverage for more than 50 million of America's seniors and those living with chronic diseases like lupus. Part D allows timely, affordable access to ...

A new study has found that women with systemic lupus erythematosus who have problems with memory and thinking (mild cognitive impairment, or MCI) exhibit morphological brain changes, which may serve ...

In a new study, researchers found people with clinically active systemic lupus erythematosus (SLE) disease on standard of care can attain or achieve low disease activity (LLDAS) and meet the ...